UnknownPhase 4ketamine
Hyperventilation Combined With Etomidate or Ketamine Anesthesia in ECT Treatment of Major Depression
Sponsored by University of Manitoba
NCT ID
NCT02924090
Target Enrollment
48 participants
Start Date
2016-09
Est. Completion
2018-12
About This Study
This is a randomized controlled study assessing the effect of pre-emptive hyperventilation on ECT seizure duration, cerebral desaturation and remission of depressive symptoms in patients with Major Depressive Disorder. Comparison of etomidate and ketamine on remission of depressive symptoms with and without pre-emptive hyperventilation will also be studied.
Conditions Studied
Interventions
- •Etomidate
- •Ketamine
- •Hyperventilation
- •Electroconvulsive therapy (ECT)
Eligibility
Age:18 Years - 85 Years
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria: * Adults patients aged 18 to 85 years * Diagnosed with Major Depressive Disorder, unipolar or bipolar depression * Undergoing ECT for treatment of their symptoms * Currently residing in Manitoba Exclusion Criteria: * Relative contraindications to ECT therapy (recent MI or CVA, increased intracranial pressure, intracranial mass lesion, intracranial aneurysm, epilepsy, known cardiac arrhythmia, pheochromocytoma, pregnancy) * Contraindications to etomidate (sepsis, primary or secondary adrenal insufficiency, porphyria) * DSM-V diagnosis of a lifetime history of psychotic spectrum disorder * Drug or alcohol dependence, or abuse within the past 3 months, soy-bean oil allergy
Study Locations (1)
Health Sciences Centre
Winnipeg, Manitoba, Canada